Crossreactivity of bupropion metabolite with enzyme-linked immunosorbent assays designed to detect amphetamine in urine

Lisa Reidy, H. Chip Walls, Bernard W Steele

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Drug screening is rapid, inexpensive, and is often used in clinical, forensic, and workplace drug testing to gain informative results. This article seeks to determine if bupropion and/or its metabolites is resulting in false-positive amphetamine screening results in our case samples using commercially available enzymelinked immunosorbent assay tests. Method: Fortified urine and forensic case samples were used to determine crossreactivity of bupropion and its main metabolite to four different amphetamine and methamphetamine enzyme-linked immunosorbent assay kits. Results: Two of the enzyme-linked immunosorbent assay kits used to screen for amphetamine may result in false-positive results if bupropion metabolites are present in concentrations greater than 500 ng/mL. Three case samples gave a positive screen results for amphetamine using Amphetamine ULTRA kits, yet no amphetamines were confirmed by gas chromatography-mass spectrometry and all samples were positive for bupropion and metabolites. Conclusions: Laboratory directors and clinicians should be aware of the characteristic of their chosen laboratory assay and should communicate this to physicians so that results can be interpreted accurately.

Original languageEnglish
Pages (from-to)366-368
Number of pages3
JournalTherapeutic Drug Monitoring
Volume33
Issue number3
DOIs
StatePublished - Jun 1 2011

Fingerprint

Bupropion
Amphetamine
Enzyme-Linked Immunosorbent Assay
Urine
Amphetamines
Immunosorbents
Preclinical Drug Evaluations
Methamphetamine
Workplace
Gas Chromatography-Mass Spectrometry
Physicians
Pharmaceutical Preparations

Keywords

  • Amphetamine
  • Bupropion metabolite
  • ELISA
  • False-positive

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Crossreactivity of bupropion metabolite with enzyme-linked immunosorbent assays designed to detect amphetamine in urine. / Reidy, Lisa; Walls, H. Chip; Steele, Bernard W.

In: Therapeutic Drug Monitoring, Vol. 33, No. 3, 01.06.2011, p. 366-368.

Research output: Contribution to journalArticle

@article{ff99e779e5e34eaebf26c8e2ae40e0d3,
title = "Crossreactivity of bupropion metabolite with enzyme-linked immunosorbent assays designed to detect amphetamine in urine",
abstract = "Background: Drug screening is rapid, inexpensive, and is often used in clinical, forensic, and workplace drug testing to gain informative results. This article seeks to determine if bupropion and/or its metabolites is resulting in false-positive amphetamine screening results in our case samples using commercially available enzymelinked immunosorbent assay tests. Method: Fortified urine and forensic case samples were used to determine crossreactivity of bupropion and its main metabolite to four different amphetamine and methamphetamine enzyme-linked immunosorbent assay kits. Results: Two of the enzyme-linked immunosorbent assay kits used to screen for amphetamine may result in false-positive results if bupropion metabolites are present in concentrations greater than 500 ng/mL. Three case samples gave a positive screen results for amphetamine using Amphetamine ULTRA kits, yet no amphetamines were confirmed by gas chromatography-mass spectrometry and all samples were positive for bupropion and metabolites. Conclusions: Laboratory directors and clinicians should be aware of the characteristic of their chosen laboratory assay and should communicate this to physicians so that results can be interpreted accurately.",
keywords = "Amphetamine, Bupropion metabolite, ELISA, False-positive",
author = "Lisa Reidy and Walls, {H. Chip} and Steele, {Bernard W}",
year = "2011",
month = "6",
day = "1",
doi = "10.1097/FTD.0b013e3182126d08",
language = "English",
volume = "33",
pages = "366--368",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Crossreactivity of bupropion metabolite with enzyme-linked immunosorbent assays designed to detect amphetamine in urine

AU - Reidy, Lisa

AU - Walls, H. Chip

AU - Steele, Bernard W

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Background: Drug screening is rapid, inexpensive, and is often used in clinical, forensic, and workplace drug testing to gain informative results. This article seeks to determine if bupropion and/or its metabolites is resulting in false-positive amphetamine screening results in our case samples using commercially available enzymelinked immunosorbent assay tests. Method: Fortified urine and forensic case samples were used to determine crossreactivity of bupropion and its main metabolite to four different amphetamine and methamphetamine enzyme-linked immunosorbent assay kits. Results: Two of the enzyme-linked immunosorbent assay kits used to screen for amphetamine may result in false-positive results if bupropion metabolites are present in concentrations greater than 500 ng/mL. Three case samples gave a positive screen results for amphetamine using Amphetamine ULTRA kits, yet no amphetamines were confirmed by gas chromatography-mass spectrometry and all samples were positive for bupropion and metabolites. Conclusions: Laboratory directors and clinicians should be aware of the characteristic of their chosen laboratory assay and should communicate this to physicians so that results can be interpreted accurately.

AB - Background: Drug screening is rapid, inexpensive, and is often used in clinical, forensic, and workplace drug testing to gain informative results. This article seeks to determine if bupropion and/or its metabolites is resulting in false-positive amphetamine screening results in our case samples using commercially available enzymelinked immunosorbent assay tests. Method: Fortified urine and forensic case samples were used to determine crossreactivity of bupropion and its main metabolite to four different amphetamine and methamphetamine enzyme-linked immunosorbent assay kits. Results: Two of the enzyme-linked immunosorbent assay kits used to screen for amphetamine may result in false-positive results if bupropion metabolites are present in concentrations greater than 500 ng/mL. Three case samples gave a positive screen results for amphetamine using Amphetamine ULTRA kits, yet no amphetamines were confirmed by gas chromatography-mass spectrometry and all samples were positive for bupropion and metabolites. Conclusions: Laboratory directors and clinicians should be aware of the characteristic of their chosen laboratory assay and should communicate this to physicians so that results can be interpreted accurately.

KW - Amphetamine

KW - Bupropion metabolite

KW - ELISA

KW - False-positive

UR - http://www.scopus.com/inward/record.url?scp=80051795658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051795658&partnerID=8YFLogxK

U2 - 10.1097/FTD.0b013e3182126d08

DO - 10.1097/FTD.0b013e3182126d08

M3 - Article

C2 - 21436763

AN - SCOPUS:80051795658

VL - 33

SP - 366

EP - 368

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 3

ER -